Moderna (MIL:1MRNA) Construction In Progress : €1,009 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Moderna Construction In Progress?

Moderna's quarterly construction in progress declined from Jun. 2024 (€893 Mil) to Sep. 2024 (€878 Mil) but then increased from Sep. 2024 (€878 Mil) to Dec. 2024 (€1,009 Mil).

Moderna's annual construction in progress increased from Dec. 2022 (€265 Mil) to Dec. 2023 (€789 Mil) and increased from Dec. 2023 (€789 Mil) to Dec. 2024 (€1,009 Mil).

Moderna Construction In Progress Historical Data

The historical data trend for Moderna's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Construction In Progress Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

28.77

187.62

265.26

788.62

1,009.44

Moderna Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Construction In Progress	Get a 7-Day Free Trial															788.62	795.80	892.77	878.48	1,009.44

Moderna Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Moderna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (MIL:1MRNA) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil 0QF:Bulgaria MRNA:Austria

Address

325 Binney Street, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Headlines

No Headlines